Volume 11,Issue 2
Review of the Nursing Monitoring System for Adverse Events Related to Immunotherapy in Advanced Lung Cancer
Immunotherapy with immune checkpoint inhibitors for advanced lung cancer is prone to inducing immune-related adverse events (irAEs), which may limit therapeutic benefits. Based on existing literature, this study systematically reviews the risk factors and epidemiological characteristics of irAEs, analyzes changes in toxicity profiles under combination therapy regimens, and examines the association between irAEs and treatment efficacy. A comprehensive nursing monitoring system was established, encompassing baseline assessment, hierarchical risk stratification, multidisciplinary collaboration, and long-term follow-up. By integrating high-risk factor identification, core element frameworks, and tiered intervention strategies, a dynamic monitoring protocol based on risk stratification and structured patient education pathways was proposed to achieve early detection and standardized management of irAEs, thereby providing evidence-based nursing practice for immunotherapy safety in advanced lung cancer.
[1] Xu W, Ji N, Lin D, 2023, Risk factors for immune-related adverse reactions in patients with advanced lung cancer after treatment with immune checkpoint inhibitors., Shandong Medical Journal, 63(36): 87-90.
[2] Qin Q, Wang J, Wang H, 2020, Systematic review and meta-analysis of immune-related adverse events associated with ICIs in the treatment of advanced non-small cell lung cancer., China Lung Cancer Journal, 23(09): 772-791.
[3] Wan S, Zhang P, 2026, Neoadjuvant immunotherapy: A new hope for the treatment of locally advanced lung cancer patients., World Science, (03): 28-31.
[4] Yuan X, Li Y, Liu C, et al., 2026, Application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer., Chinese Journal of Geriatric Multivisceral Diseases, 25(02): 97-101.
[5] Luan T, Ma K, Sun J, et al., 2025, Advances in immunotherapy for advanced lung cancer., China Journal of Practical Internal Medicine, 45(12): 1043-1048.
[6] Mao X, Yin X, Shi G, et al., 2025, Clinical efficacy and safety of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer patients., China Anti-Tuberculosis Journal, 47(S2): 171-175.
[7] Zhang C, Chen P, 2025, Research progress on the predictive value of immune-related adverse events in the efficacy of immunotherapy for extensive-stage small cell lung cancer., China Oncology Clinical, 52(15): 801-806.
[8] Wang L, Xie X, Lin X, et al., 2025, Balance strategy between efficacy of individualized immunotherapy and immune-related adverse reactions in advanced lung cancer., China Journal of Practical Internal Medicine, 45(06): 471-476.
[9] Liu Q, Shang L, 2022, Research progress on the correlation between adverse reactions related to immunotherapy and efficacy in advanced non-small cell lung cancer., Journal of Practical Oncology, 36(05): 463-467.
[10] Wang Y, Zhang R, 2020, Adverse reactions associated with immune checkpoint inhibitor therapy for advanced lung cancer and progress in diagnosis and treatment., Zhejiang Medical Journal, 42(12): 1227-1231+1241.